Послеоперационная радиотерапия немелкоклеточного рака легкого: аргументы за

Послеоперационная радиотерапия немелкоклеточного рака легкого: аргументы за

Автор: Муфазалов Ф.Ф., Шарипова Н.С.

Журнал: Злокачественные опухоли @malignanttumors

Рубрика: Медицинские науки

Статья в выпуске: 3 (10), 2014 года.

Бесплатный доступ

Послеоперационная радиотерапия, немелкоклеточный рак легкого

Короткий адрес: https://sciup.org/14045510

IDR: 14045510

Список литературы Послеоперационная радиотерапия немелкоклеточного рака легкого: аргументы за

  • Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012;62:10-29
  • Состояние онкологической помощи населению России в 2013 году\\под редакцией А. Д. Каприна, В. В. Старинского Г. В. Петровой; М-2014
  • Mountain CF. Revisions in the International System for staging lung cancer.Chest. 1997;111 (6):1710-7
  • Bakira M, Fraser S, RoutledgeIs T et al. Is surgery indicated in patients with stage IIIa lung cancer and mediastinal nodal involvement? InteractCardiovascThoracSurg 2011; 13: 303-310
  • Koike T, Yamato Y, Yoshiya K et al. Intentional limited pulmonary resection for peripheral T1 N0 M0 small-sized lung cancer. J ThoracCardiovascSurg 2003;125: 924-928
  • Maeda R, Yoshida J, Ishii G et al. Risk factors for tumor recurrence in patients with early-stage (stage I and II) non-small cell lung cancer: Patient selection criteria for adjuvant chemotherapy according to the 7th edition TNM classification. Chest 2011; 140: 1494-1502
  • Manser R, Wright G, Hart D, Byrnes G, Campbell DA. Surgery for early stagenon-small cell lung cancer. Cochrane Database Syst Rev 2005: CD004699
  • Le Chevalier T. Adjuvant chemotherapy for resectable non-small-cell lung cancer: where is it going? Ann Oncol. 2010; Suppl 7: vii 196-8
  • Groome PA, Bolejack V, Crowley JJ, et al. The IASLC Lung Cancer Staging Project: validation of the proposals for revision of the T, N, and M descriptors and consequent stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. J ThoracOncol 2007;2:694-705
  • Thomas WS, Joseph L, Ronald BP, Valerie WR. General thoracic surgery, vol.6. Philadelphia: Lippincott Williams & Wilkins; 2005. p. 1653
  • Non Small Cell Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomized clinical trials. Br Med J 1995;311:899-909
  • International Adjuvant Lung cancer Trial Collaborative Group. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. New Engl J Med 2004;350:351-60
  • Strauss GM, Herndon 2nd JE, Maddaus MA, et al. Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups. J ClinOncol 2008;26:5043-51
  • Winton TL, Livingston R, Johnson D, et al. For the National Cancer Institute of Canada Clinical Trials Group and the National Cancer Institute of the United States Intergroup JBR.10 Trial Investigators Vinorelbine plus cisplatinvs observation in resected non-small cell lung cancer Intergroup. New Engl J Med 2005;352:2589-97
  • Douillard JY, Rosell R, De Lena M, et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association ): a randomised controlled trial. Lancet Oncol 2006;7:719-27
  • NSCLC Meta-analyses Collaborative Group. Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient data. Lancet 2010;375:1267-77
  • PORT Meta-analysis Trialists Group. Post-operative radiotherapy in non-small cell lung cancer: systematic review and meta-analysis of individual patient data from nine randomised controlled trials. Lancet 1998;352:257-63
  • Burdett S, Stewart LOn behalf of the PORT Meta-analysis Group. Postoperative radiotherapy in non-small-cell Lung Cancer: update of an individual patient data meta-analysis. Lung Cancer 2005;47:81-3
  • Burdett S, Rydzewska L, Tierney JF, Fisher DJ. A closer look at the effects of postoperative radiotherapy by stage and nodal status: updated results of an individual participant data meta-analysis in non-small-cell Lung Cancer. Lung Cancer 2013;80:350-2
  • Bekelman JE, Rosenzweig KE, Bach PB, et al. Trends in the use of postoperative radiotherapy for resected non-small-cell lung cancer. Int J RadiatOncolBiolPhys 2006;66:492-499.
  • Jeffrey A. Bogart1 and Jesse N. Aronowitz2 Localized Non^Small Cell Lung Cancer: Adjuvant Radiotherapy in the Era of Effective Systemic Therapy Clin Cancer Res 2005;11 (13 Suppl) July 1, 2005
  • Philips P, RocmansP, Vanderhoef P, Van HoutteP.Postop erativeradiotherapyafterpneumonectomy: impact of modern treatment facilities. IntJRadiatOncolBiol Phys1993;27:525^9
  • MunroAJ. What now for postoperative radiotherapy for lung cancer? Lancet1998;352:250^1
  • Lung Cancer Study Group. Effects of post-operative mediastinal radiation on completely resected stage II and stage III epidermoid cancer of the lung. N Engl J Med 1986;315:1377-81
  • Dautzenberg B, Arriagada R, Chammard AB, etal. A controlled study of postoperative radiotherapy for patients with completely resected nonsmall cell lung carcinoma. Cancer 1999; 86: 265^73
  • Trodella L, Granone P, Valente S, et al. Adjuvant radiotherapy in non-small cell lung cancer with pathological stage I: definitive results of a phase II randomized trial. RadiotherOncol 2002;62:11^9
  • Sawyer T.E., Bonner JA, Gould PM, et al. Effectiveness of postoperative irradiation in stage IIIA nonsmall cell lung cancer according to regression tree analyses of recurrence risks. Ann ThoracSurg 1997;64:1402^8
  • Machtay M, Lee JH, Sjrager JB, Kaiser LR, Gladstein E. Risk of death from intercurrent disease is not excessively increased by modern post-operative radiotherapy for high risk resected nonsmall cell lung carcinoma. J ClinOncol 2001;1119: 3912^7
  • Rescigno J. Use of postoperative radiotherapy for node-positive non-small-cell lung cancer. Clin Lung Cancer 2002;4:35^44
  • Kepka L, Bujko K, Orlowski TM, et al. Cardiopulmonary morbidity and quality of life in non-small cell lung cancer patients treated with or without postoperative radiotherapy. RadiotherOncol 2011;98:238-43.
  • Fan etal.Risk factors for locoregional recurrence in patientswith resected N1 non-small cell lung cancer: a retrospective study to identify patterns of failure and implications for adjuvant radiotherapy Radiation Oncology 2013, 8:286
  • Koo HK, Jin SM, Lee CH et al. Factors associated with recurrence in patients with curatively resected stage I-II Lung Cancer. Lung Cancer 2011; 73: 222-229
  • Luzzi L, Voltolini L, CampioneA et al. Pneumonectomyvs lobectomy in the treatment of pathologic N1 NSCLC: could the type of surgical resection dictate survival? J CardiovascSurg (Torino) 2003; 44: 119-123
  • Sawyer TE, Bonner JA, Gould PM et al. Factors predicting patterns of recurrence
  • Lopez J. L.et al Risk factors for local and regional recurrence in patients with resected N0-N1 non-small-cell lung cancer, with implications for patient selection for adjuvant radiation therapy Annals of Oncology 0: 1-8, 201
  • Nathan M. Mollberg et al. Lymphovascular Invasion as a Prognostic Indicator in Stage I Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis Ann ThoracSurg 2014;97:965-72
  • Martini N, Kris MG, Flehinger BJ, et al. Preoperative chemotherapy for stage IIIa (N2) lung cancer: the Sloan-Kettering experience with 136 patients. Ann ThoracSurg 1993;55:1365-73
  • Andre´ F, Grunenwald D, Pignon JP, et al. Survival of patientswith resected N2 non-small cell lung cancer: evidence for a subclassification and implications. J ClinOncol 2001;16:2981-9
  • van Meerbeeck JP, Kramer GW, Van Schil PE, etalfor the European Organisation for Research and Treatment of Cancer-Lung Cancer Group. Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small-cell lung cancer. J Natl Cancer Inst2007;99:442-50
  • Betticher DC. Hsu Schmitz SF, Tötsch M, et al. Mediastinal lymph node clearance after docetaxel-cisplatinneoadjuvant chemotherapy is prognostic of survival in patients with stage IIIA pN2 non-small-cell lung cancer: a multicenter phase II trial. J ClinOncol 2003;21:1752-9
  • Burdett S, Stewart LA, Rydzewska L. A systematic review and meta-analysis of the literature: chemotherapy and surgery versus surgery alone in non-small cell lung cancer. J ThoracOncol 2006;1:611-21
  • Betticher DC, Hsu Schmitz S-F, Totsch M, et alfor the Swiss Group for Clinical Cancer Research (SAKK). Prognostic factors affecting long-term outcomes in patients with resected stage IIIA pN2 non-small-cell lung cancer: 5-year follow-up of a phase II study. Br J Cancer 2006;94:1099-106
  • Amini A, Lou F, Correa AM, et al. Predictors for locoregional recurrence for clinical stage III-N2 non-small cell lung cancer with nodal downstaging after induction chemotherapy and surgery. Ann SurgOncol 2013;20:1934-40
  • Lardinois D, De Leyn P, Van Schil P, et al. ESTS guidelines for intraoperative lymph node staging in non-small cell lung cancer. Eur J Cardiothorac Surg 2006;30:787-92
  • De Leyn P, Lardinois D, Van Schil PE, et al. ESTS guidelines for preoperative lymph node staging for non-small cell lung cancer. Eur J Cardiothorac Surg 2007;32:1-8
  • Rami-Porta R, WittekindCGoldstraw for the International Association for the Study of Lung Cancer (IASLC) staging committee. Complete resection of Lung Cancer surgery: proposed definition. Lung Cancer 2005;49:25-33
  • Le Pe´choux C, Dunant A, Pignon JP, et al. Need for a new trial to evaluate adjuvant postoperative radiotherapy in nonsmall-cell lung cancer patients with N2 mediastinal involvement. J ClinOncol 2007;25: e10-1
Еще
Статья
SciUp 2024 © 2024 ©